We are live on ! Find out more
ACM

Asymmetry Capital Management Portfolio holdings

AUM $188M
1-Year Est. Return 44.72%
This Fund
S&P 500
This Quarter Est. Return
+9.67%
1 Year Est. Return
+44.72%
3 Year Est. Return
+299.95%
5 Year Est. Return
+628.83%
10 Year Est. Return
–
AUM
$193M
AUM Growth
-$26M
Cap. Flow
-$20.8M
Cap. Flow %
-10.75%
Top 10 Hldgs %
57.01%
Holding
46
New
13
Increased
3
Reduced
13
Closed
17

Top Buys

Rank Stock Value
1
ADPT icon
Adaptive Biotechnologies
ADPT
+$15.6M
2
SHC icon
Sotera Health
SHC
+$12.4M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$11.8M
4
AZN icon
AstraZeneca
AZN
+$11M
5
UNH icon
UnitedHealth
UNH
+$10.2M

Top Sells

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$21.2M
2
LAB icon
Standard BioTools
LAB
+$9.27M
3
SAGE
Sage Therapeutics
SAGE
+$8.36M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$7.73M
5
CDXS icon
Codexis
CDXS
+$6.95M

Sector Composition

Rank Sector Weight
1 Healthcare 99.55%
2 Financials 0.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FBRX icon
26
Forte Biosciences
FBRX
$1.57B
$1.82M 0.94%
2,128
-1,272
-37% -$1.04M
TPTX
27
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$1.12M 0.58%
+11,873
New +$1.41M
BLSA
28
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$871K 0.45%
82,377
-6,758
-8% -$76.3K
DMRA
29
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.82B
$690K 0.36%
4,541
-8,953
-66% -$2.44M
BMRN icon
30
BioMarin Pharmaceuticals
BMRN
$13.3B
– –
-88,195
Closed -$7.73M
BNR
31
Burning Rock Biotech
BNR
$115M
– –
-21,773
Closed -$5.03M
CCCC icon
32
C4 Therapeutics
CCCC
$400M
– –
-139,343
Closed -$4.62M
CDXS icon
33
Codexis
CDXS
$161M
– –
-318,492
Closed -$6.95M
ELDN icon
34
Eledon Pharmaceuticals
ELDN
$284M
– –
-80,069
Closed -$1.23M
FATE icon
35
Fate Therapeutics
FATE
$322M
– –
-50,709
Closed -$4.61M
KALV
36
DELISTED
KalVista Pharmaceuticals
KALV
– –
-46,910
Closed -$891K
LAB icon
37
Standard BioTools
LAB
$310M
– –
-1,544,904
Closed -$9.27M
NCNA
38
NuCana
NCNA
$5.99M
– –
-123
Closed -$2.76M
ORIC icon
39
Oric Pharmaceuticals
ORIC
$1.41B
– –
-67,210
Closed -$2.27M
STRO icon
40
Sutro Biopharma
STRO
$423M
– –
-15,758
Closed -$3.42M
TXG icon
41
10x Genomics
TXG
$7.44B
– –
-37,587
Closed -$5.32M
VTGN icon
42
VistaGen Therapeutics
VTGN
$11.7M
– –
-74,660
Closed -$4.34M
VTRS icon
43
Viatris
VTRS
$18.7B
– –
-1,130,504
Closed -$21.2M
WVE icon
44
Wave Life Sciences
WVE
$1.2B
– –
-280,924
Closed -$2.21M
ITCI
45
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-130,654
Closed -$4.16M
BMY.RT
46
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
– –
-5,152,098
Closed -$3.56M
1
2

Similar funds

FAC
Forrestal Agricultural Corporation Princeton, New Jersey $183M AUM
SWM
Strategic Wealth Management Kirkland, Washington $202M AUM 9.35% 1-Year Est. Return
MC
MRJ Capital New York $173M AUM 31.99% 1-Year Est. Return
KM
Kylin Management New York $173M AUM 39.51% 1-Year Est. Return
TI
Truehand Inc Strafford, New Hampshire $171M AUM 25.9% 1-Year Est. Return
GC
Grace Capital Quincy, Massachusetts $168M AUM 21.6% 1-Year Est. Return
REMS
Real Estate Management Services $167M AUM 37.69% 1-Year Est. Return
NM
Nokota Management New York $165M AUM

Asymmetry Capital Management's Q1 2021 Portfolio in Review

As of Q1 2021, Asymmetry Capital Management held 46 positions worth $193M, down 12% from $219M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Asymmetry Capital Management withdrew a net $20.8M in Q1 2021, closing 17 positions and reducing 13 holdings. Its most notable exit was Viatris, an estimated $21.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier, followed by Financials.

Against the trend, Asymmetry Capital Management opened a new position in Adaptive Biotechnologies worth $11.6M.

  • Asymmetry Capital Management's largest Q1 2021 buy was Adaptive Biotechnologies: 287,490 shares worth $11.6M.
  • Asymmetry Capital Management added most to Arena Pharmaceuticals Inc in Q1 2021, an estimated $4.76M increase.
  • Asymmetry Capital Management's biggest Q1 2021 reduction was Sage Therapeutics, cutting an estimated $8.36M.
  • Asymmetry Capital Management fully exited Viatris in Q1 2021, selling an estimated $21.2M.
  • Asymmetry Capital Management's ten largest holdings make up 57% of its $193M portfolio in Q1 2021.
  • Asymmetry Capital Management opened 13 new positions and closed 17 in Q1 2021.
  • Asymmetry Capital Management's portfolio value fell 12% quarter-over-quarter to $193M.

Based on Asymmetry Capital Management's 13F filing for Q1 2021, filed 11 May 2021.